| Interaction ID | Mol A | Type | Species | Verb | Nature | Mol B | Type | Species |   |
|---|
|
| 67445 | Rosiglitazone | Small molecule | Small molecule | Decreases expression | indirect | TNF | Protein | Homo sapiens | | | MMP-9 levels are increased in type 2 diabetic
patients with CAD, and treatment of these patients with the
antidiabetic PPARgamma-activator rosiglitazone significantly
reduces MMP-9, tumor necrosis factor-alpha, and SAA serum levels. | | | |
Interaction id | 67445 | |
MOLECULE A | |
Id | 122320-73-4 |
Type | Small molecule |
Species | Small molecule | |
Attribute |
--
|
Structure Details | -- |
Disease Details | -- | |
MOLECULE B | |
Id | 7124 |
Type | Protein |
Species | Homo sapiens | |
Attribute | -- |
Structure Details | -- |
Disease Details | disease: :Coronary Arteriosclerosis:Diabetes
Mellitus, Type 2 | | Kinetics | - | |
|
General Information |
Interaction term | Decreases expression (
indirect ) | |
Pathway | Ligand-dependent nuclear receptor
activity:Peroxisome proliferator associated receptor activity | |
Disease Details | | disease: :Coronary Arteriosclerosis:Diabetes
Mellitus, Type 2 |
| |
Experimental location and method | - species::Type 2 diabetic patients with
coronary artery disease
| |
References | |
PubMed Id | 12588772 | |
Author | Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A,
Scharnagl H, Hombach V, Koenig W | |
Title | Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9
serum levels in type 2 diabetic patients with coronary artery disease. |
|
|
| |
|
d: for diseases
Disease